NCT00025233View on ClinicalTrials.gov

Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Cervical Squamous Cell CarcinomaRecurrent Cervical Cancer
Interventions
BIOLOGICAL

bevacizumab

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00025233 - Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix | Biotech Hunter | Biotech Hunter